Viking Therapeutics, Inc.'s VK2735 has potential as a GLP-1 for obesity amid Pfizer's exit, but competition and financing ...

Shares of Viking Therapeutics (VKTX) and Structure Therapeutics (GPCR) are on the rise on Monday after Pfizer (PFE) announced its decision to discontinue development of danuglipron, an oral ...

So far this year, Pfizer shares have dropped 17.4%, while Novo Nordisk's stock has tumbled 24% and Lilly shares have slipped 3.2%. The SPDR S&P Pharmaceuticals ETF XPH has shed 12.1% year to date and ...

Shares of Structure Therapeutics Inc ADR (NASDAQ: GPCR) climbed 6.8% following the news that Pfizer Inc. (NYSE: NYSE:PFE) has discontinued the development of its obesity drug candidate, danuglipron.

Viking Therapeutics enjoyed a nice share rally on the news that rival Pfizer is discontinuing obesity candidate danuglipron.

Pfizer ends danuglipron development after liver safety issue, boosting shares of Viking, Eli Lilly, and Novo Nordisk amid ...

With Semaglutide, postmenopausal women can achieve significant weight loss, improve insulin sensitivity, and lower the risk ...

Advances recognized by science’s most lucrative awards include high-energy physics experiments and groundbreaking weight-loss ...

Experts across healthcare debunk 15 common myths about GLP-1 medications—covering everything from access and cost to ...

Originally developed to treat diabetes, these drugs work by mimicking a hormone called glucagon-like peptide 1 (GLP-1), which ...

Structure Therapeutics Inc.’s GPCR share price has dipped by 12.27%, which has investors questioning if this is right time to buy.